


Disclaimer

- I am making this presentation as an independent agent
- I am not making this presentation as a representative of USP, PDA, ASM, USA, BSA, or any other organization with which I am currently associated.
- The views expressed in this presentation are offered as mine alone.




- · What's in this for Me?
- What is the USP?
- Parts of the USP
- Specific Interest for Pharmacists
- Specific Interest for Outsourcing Facilities
- Conclusions/Summary






	Percentage
483 Topic	Occurren
Stability Program	80.0%
Validation of Sterilization - Media Fills	80.0%
Inadequate/ Improper Environmental Monitoring	80.0%
SOPs to Prevent Microbial Contamination	72.9%
Inadequate Gowning	72.9%
Lab Procedures: Testing/ Contract Lab Control	70.0%
Batch Release	61.4%
Inadequate Cleaning/ Disinfection	60.0%
Control of Equipment	58.6%
Inadequate Facility / Smoke Studies	52.9%
Investigations	48.6%
Control of Pyrogenic Contamination	44.3%
QAU Not Effective/ Production SOPs not followed/effective	ve 42.9%
Separation of Clean and Dirty Operations/Storage of Mat	terials 30.0%



- · What's in this for me?
- What is the USP?
- Parts of the USP
- Specific Interest for Pharmacists
- Specific Interest for Outsourcing Facilities
- Conclusions/Summary







USP 37-NF 32 (2014)

- Time-tested, international resource.
 USP standards are used in more than 130 countries
- ► More than 6,000 monographs



- ► Continuously updated—published annually in a main edition and two *Supplements*
- ► Available in English (print, online, CD) and Spanish (print)




USP's Legal Recognition (FD&C Act)

- SEC. 201. For the purposes of this chapter -
 - (g)(1) The term "drug" means articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them
 - (j) The term "official compendium" means the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, official National Formulary, or any supplement to any of them.



USP's Legal Recognition: FD&C Act Section 501(b) Adulteration

- A drug or device shall be deemed to be adulterated if it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standards set forth in such compendium.
- Such determination as to strength, quality, or purity shall be made in accordance with the tests or methods of assay set forth in such compendium...



USP for Compounding Pharmacies

USP provides both general chapters and monographs for compounded preparations. Compounded preparation monographs may include

- Formulas (ingredients and quantities)
- Specific directions to correctly compound the particular preparation
- · Packaging and storage information
- · Labeling information
- pH
- Beyond-use dates (BUD) based on stability studies
- Detailed assays (majority of monographs)



USP for Compounding Pharmacies

Standards in USP–NF for compounded preparations may be enforced by both

- States as pharmacy practice/compounding is traditionally regulated by state boards of pharmacy
- FDA as compounded preparations remain subject to the adulteration and misbranding provisions of the FD&C Act which require conformance to certain USP–NF standards



USP-NF

USP–NF is a combination of two compendia, the United States Pharmacopeia (USP) and the National Formulary (NF). Monographs for drug substances, dosage forms, and compounded preparations are featured in the USP. Monographs for dietary supplements and ingredients appear in a separate section of the USP. Excipient monographs are in the NF.



Parts of USP – 2014 (4 volumes)

Volume 1

- Front Matter
- General Notices
- General Chapters
 - Referee Chapters (<1000)
 - Informational Chapters (>1000)
 - Dietary Supplements Chapters (>2000)
- · Reagents, Indicators and Solutions
- Reference Tables



Parts of USP – 2014 (4 volumes)

Volume 2

USP Monographs A-I

Volume 3

USP Monographs J-Z

Volume 4

Dietary Supplements



USP General Notices

- Title and Revision
- · Official Status and Legal Recognition
- Conformance to Standards
- Monographs and General Chapters
- Monograph Components
- Testing Practices and Procedures
- Test Results
- · Terms and Definitions
- · Prescribing and Dispensing
- · Preservation, Packaging, Storage and Labeling




- What's in this for Me?
- What is the USP?
- Parts of the USP
- Specific Interest for Pharmacists
- Specific Interest for Outsourcing Facilities
- Conclusions/Summary





For Compounding Pharmacists


- Monographs
- · USP Compounding Specific Chapters
 - USP <795> Pharmaceutical Compounding Nonsterile Preparations
 - USP <797> Pharmaceutical Compounding Sterile Preparations
 - USP <1163> Quality Assurance in Pharmaceutical Compounding
- Others























- What's in this for Me?
- What is the USP?
- Parts of the USP

Unique Pharmaceuticals, Ltd., Temple TX

US Specialty Formulations LLC, Bethlehem, PA

US Compounding, Inc., Conway, AR

- · Specific Interest for Pharmacists
- Specific Interest for Outsourcing Facilities
- Conclusions/Summary




1/22/2014 Advanced Pharma, Inc., Houston, TX http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ PharmacyCompounding/ucm378645.htm#1 Allergy Laboratories, Inc., Oklahoma City, OK 12/30/2013 Banner Health, Chandler, AZ 12/26/2013 Cantrell Drug Company, Litte Rock, AR 12/16/2013 Edge Pharmacy Services LLC, Colchester, VT 1/21/2014 Infusion Options INC., Brooklyn, NY 1/24/2014 JCB Laboratories, North Wichita, KS 1/21/2014 Kings Park Slope, Inc., Brooklyn, NY 12/23/2013 KRS Global Biotechnology, Inc., Boca Raton, FL 12/15/2013 1/31/2014 Leiter's Compounding, (Great Oaks Blvd), San Jose, CA Marlborough Hospital, Marlborough, MA 12/26/2013 Medi-Fare Drug & Home Health Center, Inc., Blacksburg SC 12/17/2013 Pharmagen Laboratories Inc., Stamford, CT 1/21/2014 Pharmakon Pharmaceuticals, Noblesville, IN 1/23/2014 PharMedium Services, LLC, Cleveland, MS 12/11/2013 PharMedium Services, LLC, Edison, NJ 12/11/2013 PharMedium Services, LLC, Memphis, TN 12/11/2013 PharMedium Services, LLC, Sugarland, TX 12/11/2013 Region Care, Inc., Great Neck, NY 12/24/2013 SCA Pharmaceuticals, Little Rock, AR 12/13/2013 Triangle Compounding Pharmacy Inc., Cary, NC 1/24/2014


1/24/2014


12/20/2013


1/31/2014


24 Outsourcing Facilities (2/7/14)

















	Percentag
483 Topic	Occurren
Stability Program	80.08
Validation of Sterilization - Media Fills	80.08
Inadequate/ Improper Environmental Monitoring	80.08
SOPs to Prevent Microbial Contamination	72.99
Inadequate Gowning	72.99
Lab Procedures: Testing/ Contract Lab Control	70.09
Batch Release	61.49
Inadequate Cleaning/ Disinfection	60.09
Control of Equipment	58.69
Inadequate Facility / Smoke Studies	52.99
Investigations	48.69
Control of Pyrogenic Contamination	44.39
QAU Not Effective/ Production SOPs not followed/effective	e 42.9°
Separation of Clean and Dirty Operations/Storage of Mate	erials 30.0°







- What's in this for Me?
- What is the USP?
- · Parts of the USP
- Specific Interest for Pharmacists
- Specific Interest for Outsourcing Facilities
- Conclusions/Summary



	Percentage
483 Topic	Occurrence
Stability Program	80.0%
Validation of Sterilization - Media Fills	80.0%
Inadequate/ Improper Environmental Monitoring	80.0%
SOPs to Prevent Microbial Contamination	72.9%
Inadequate Gowning	72.9%
Lab Procedures: Testing/ Contract Lab Control	70.0%
Batch Release	61.4%
Inadequate Cleaning/ Disinfection	60.0%
Control of Equipment	58.6%
Inadequate Facility / Smoke Studies	52.9%
Investigations	48.6%
Control of Pyrogenic Contamination	44.3%
QAU Not Effective/ Production SOPs not followed/effective	ve 42.9%
Separation of Clean and Dirty Operations/Storage of Mat	terials 30.0%

Conclusions

- Difficult for pharmacists to become expert in "GCP" as defined in the current environment
- Outsourcing Facilities are subject to GMP (as per FDA)
- Outsourcing Facilities and Pharmacies have different challenges – both need reliable information
- USP is the primary document to source this information



- What's in this for Me?
- What is the USP?
- Parts of the USP
- Specific Interest for Pharmacists
- Specific Interest for Outsourcing Facilities
- Conclusions/Summary



Microbiology Network

- Consulting
 - Contamination Control/Sterility Assurance
 - Quality Assurance
 - Audits
 - · Compounding Facility/Process Contamination Control
 - FDA Mock Systems Audit of Facility (w/team)
 - · Laboratory Preparation/Contract Lab Qualification
 - Quality Control
 - · Lab Operations/Design
 - · Microbiology Process/Procedures
- Training
 - In-house Training
 - Distance Training



Upcoming Webinars

- March 27th Compounding Pharmacies and the Sterility Test
- April 24th Compounding Pharmacies and Contract Testing Lab
- May 22nd Compounding Pharmacies and the Bacterial Endotoxin Test



